Depo-Estradiol Shortage: What Providers and Prescribers Need to Know in 2026

The discontinuation of brand-name Depo-Estradiol (estradiol cypionate injection, USP) by Pfizer has created a significant clinical management challenge for providers across gynecology, endocrinology, primary care, and gender-affirming medicine. This guide provides prescribers with current supply information, compounding transition guidance, dose conversion data, and patient communication strategies.

Current Supply Situation: Clinical Summary

As of 2026, the following is confirmed regarding estradiol cypionate availability:

Brand Depo-Estradiol (Pfizer): Discontinued. No longer commercially manufactured or distributed through standard pharmacy supply chains.

FDA shortage list status: Estradiol cypionate injection is not on the FDA official drug shortage list as of May 2026. The discontinuation is a business decision rather than a supply disruption, which is why it does not appear on the official list.

Compounded estradiol cypionate: Available from 503A (patient-specific) and 503B (outsourcing facility) compounding pharmacies. Common formulation: 5 mg/mL in cottonseed or grapeseed oil, 5 mL multi-dose vials.

Estradiol valerate injection (Delestrogen, generic): Available intermittently; subject to its own supply constraints in 2026. Generic estradiol valerate from Perrigo and other manufacturers provides another option.

Prescribing Transitions: Key Clinical Actions

For patients currently prescribed Depo-Estradiol, the following prescribing actions are recommended:

Update prescriptions to specify compounded estradiol cypionate. Write prescriptions as 'Estradiol Cypionate Injection (compounded), 5 mg/mL in cottonseed oil, 5 mL vial' — not by brand name. This allows any qualifying compounding pharmacy to fill the prescription.

Refer patients to compounding pharmacies. Develop a short list of PCAB-accredited 503A and 503B compounding pharmacies in your region that carry injectable estrogens. Providing this list to patients reduces the burden of searching and reduces the risk of treatment gaps.

Include backup prescriptions. Consider providing patients with a backup prescription for an alternative formulation — such as estradiol valerate injection, oral estradiol, or estradiol gel — that can be filled if compounded cypionate is unavailable.

Write formulation-flexible prescriptions where possible. For patients where clinical goals permit, consider prescribing 'estradiol cypionate 5 mg/mL OR estradiol valerate 20 mg/mL' so the pharmacist can dispense whichever is available, with appropriate dosing instructions for each.

Dose Conversion: Estradiol Cypionate to Estradiol Valerate

When switching patients from estradiol cypionate to estradiol valerate (or vice versa), dose adjustment is required. Estradiol cypionate doses are typically 20-30% lower than equivalent estradiol valerate doses due to estradiol cypionate's longer duration of action and slower release from the injection site.

Example conversion guidance (always individualize based on serum levels):

Estradiol valerate 20 mg IM every 2 weeks → approximately estradiol cypionate 5 mg IM every 2 weeks

Estradiol valerate 10 mg IM every 2 weeks → approximately estradiol cypionate 2-5 mg IM every 2 weeks

Monitor serum estradiol levels 4-8 weeks after any formulation change to confirm therapeutic ranges are maintained. For menopausal patients, target trough estradiol levels of 40-100 pg/mL. For transgender patients on feminizing HRT, target estradiol levels per Endocrine Society guidelines (100-200 pg/mL).

Patient Populations Most Affected

The Depo-Estradiol discontinuation disproportionately affects the following patient groups:

Transgender women and nonbinary individuals (AMAB): Injectable estradiol is a primary modality for gender-affirming hormone therapy. Both WPATH and Endocrine Society guidelines endorse estradiol cypionate and valerate interchangeably at doses of 2-10 mg weekly or 5-30 mg every 2 weeks for GAHT.

Women with hypogonadism: Standard dosing for hypogonadism is estradiol cypionate 1.5-2 mg IM monthly. These patients often prefer injections for convenience and reliable systemic absorption.

Menopausal patients preferring injectables: Standard dosing for vasomotor symptoms is estradiol cypionate 1-5 mg IM every 3-4 weeks. Patients who prefer injections over daily pills or weekly patches are significantly impacted.

Girls receiving puberty induction: Starting doses of 0.2 mg IM monthly gradually increasing over 2 years. Consistency of formulation is especially important during puberty induction to avoid disruption to development.

Compounding Pharmacy Quality Considerations

When referring patients to compounding pharmacies, quality assurance is critical for sterile injectable medications. Recommend the following:

PCAB (Pharmacy Compounding Accreditation Board) accreditation for 503A pharmacies

FDA registration and inspection compliance for 503B outsourcing facilities

Certificate of Analysis (CoA) availability for each batch

BUD (beyond-use dating) standards compliance per USP 797 for sterile compounding

Helping Patients Find the Medication

Providers can direct patients to medfinder for Providers to help patients locate pharmacies near them that can fill compounded estradiol cypionate prescriptions. medfinder contacts pharmacies directly to verify availability, saving patients hours of phone calls. For a full patient referral guide, see how to help your patients find Depo-Estradiol in stock.

Insurance and Coverage Guidance for Providers

Insurance coverage for compounded estradiol cypionate varies significantly by payer. Key points:

Many commercial plans do not cover compounded medications through pharmacy benefits

Medicare Part B may cover estradiol injections administered in-office as a medical benefit

Pfizer RxPathways (1-877-744-5675) offered patient assistance for brand Depo-Estradiol; this may not extend to compounded versions

Cash pricing for compounded estradiol cypionate is often $30-$80 per vial — significantly less than the $260-$310 retail price of the original brand

Summary: Key Actions for Prescribers

Update all active Depo-Estradiol prescriptions to specify compounded estradiol cypionate injection

Build a referral list of PCAB-accredited compounding pharmacies in your region

Provide backup prescriptions for alternative formulations

Monitor serum estradiol 4-8 weeks after any formulation change

Counsel patients not to abruptly discontinue estrogen therapy

Direct patients to medfinder for Providers to help locate pharmacies near them